Pediatric Arthritis Study of Certolizumab Pegol
Completed · Phase 3 · NCT01550003
Conditions: Polyarticular-course Juvenile Idiopathic Arthritis (JIA)
At a glance
- Research payments reported, 2025
- $3,470
- U.S. investigators named
- 2
- Sites paid
- 2
- Planned or actual enrollment
- 193
About the trial
- Sponsor
- UCB BIOSCIENCES GmbH (with PRA Health Sciences)
- Tested
- Certolizumab Pegol (CZP) (drug), Certolizumab Pegol (CZP) (drug)
- Dates
- Started 2012-03-08; completion 2024-04-08
- Results posted
- Yes
A Multicenter, Open-label Study to Assess the Pharmacokinetics, Safety and Efficacy of Certolizumab Pegol in Children and Adolescents With Moderately to Severely Active Polyarticular-course Juvenile Idiopathic Arthritis (JIA).
From ClinicalTrials.gov, last updated 2026-09-25. Full record, eligibility and contacts (opens in a new tab)
Industry funding
UCB GmbH reported $3,470 in research payments for this study in 2025 (2 payments).
Products named: Cimzia
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
- Consuelo D. Rabinovich, M.D. Pediatrics · Durham, NC
- Daniel J. Kingsbury, M.D. Pediatrics · Portland, OR
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Duke University Medical Center $2,921
- Legacy Emanuel Medical Center, OR $549
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.